Has Emily Li, MD received payments from drug or device companies?

Yes. Drug and device makers reported $541 in general payments to Emily Li, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Emily Li, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Emily Li, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Emily Li, MD

Ophthalmology · Seattle, WANPI 1184006298

Payments from drug & device makers

$541in general payments, 2019–2025

Across 5 payments — averaging $108.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$278
Amgen$238
Glaukos Corporation$26

What the payments were for

Food & beverage$541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	2	$278
Amgen	2	$238
Glaukos Corporation	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Clareon$184
TEPEZZA$125

How this compares

$541 in reported general payments places this provider in the 40th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington →

Medicare billing

Part B allowed, 2024

$294,015

Medicare patients

534

Services billed

4,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	211	$2,261
Doxycycline Monohydrate	32	$898
ErythromycinErythromycin Base	72	$607
Methylprednisolone	83	$531
MoxifloxacinMoxifloxacin Hcl	14	$261
Tramadol Hcl	56	$80
Triamcinolone Acetonide	12	$48
Acetaminophen-CodeineAcetaminophen With Codeine	12	$38

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Seattle

Laura PerimanSeattle$1.9M
Sheldon CowenSeattle$560K
Raghu MudumbaiSeattle$284K
Jennifer ChaoSeattle$212K
Kathryn PeppleSeattle$143K
Debarshi MustafiSeattle$85K
Michelle CabreraSeattle$75K
Paul GriggsSeattle$62K
Aaron KuzinSeattle$59K
Lisa Olmos de KooSeattle$50K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →